FUJIFILM Invests $1.2 Billion to Expand Large-Scale Cell Culture CDMO

• FUJIFILM Corporation has invested an additional $1.2 billion in its Large-Scale Cell Culture CDMO Business, bringing the total investment to over $3.2 billion.

• The investment is expected to add 8 x 20,000 litre mammalian cell culture bioreactors by 2028 and generate an additional 680 jobs by 2031.

FUJIFILM Corporation has made a significant move in the pharmaceutical industry by investing an additional $1.2 billion in its Large-Scale Cell Culture Contract Development and Manufacturing Organisation (CDMO) Business. This investment is aimed at expanding the planned FUJIFILM Diosynth Biotechnologies end-to-end bio-manufacturing facility in Holly Springs, North Carolina, bringing the total investment in the facility to over $3.2 billion.

The expansion is set to add significant large-scale production capacity to FUJIFILM Diosynth Biotechnologies’ global network through its United States and Europe manufacturing hubs. By 2031, the investment is projected to generate an additional 680 jobs, bringing the total number of new, highly skilled local jobs to 1400 in Holly Springs.

The investment will add 8 x 20,000 liters mammalian cell culture bioreactors by 2028, to the already planned 8 x 20,000 L for bulk drug substance as part of the initial investment. This new facility allows for flexibility to expand with additional bioreactors to accommodate new projects to meet the emerging needs of partners.

The strategic investment and expansion support a key pillar of FUJIFILM Diosynth Biotechnologies’ Partners for Life strategy, which is to build capacity in large-scale production in locations across the U.S. and Europe to support biopharma customers’ end-to-end needs, and provide supply chain resiliency. Through FUJIFILM Diosynth Biotechnologies’ modular production model, KojoXTM, the expansion enables the Company to construct identical large-scale production facilities in U.S. and Europe to ensure that customers can seamlessly integrate drug manufacturing production regardless of location.

“This investment is an important step to further accelerate the growth of our biopharmaceutical CDMO business,” said Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Corporation. “Fujifilm is committed to advancing a healthier society, and we are proud that our people, and this site in Holly Springs will play a vital role in supporting our partners in producing critical therapies to serve the needs of patients.” This statement underscores the company’s commitment to its Partners for Life strategy and its dedication to supporting the production of life-impacting medicines.